Sean Whalen, MD
Nuclear Medicine · New York, NYNPI 1043429152
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (40.7%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Atricure, Inc. at 39.1% of the total. Among nuclear medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 49 payments — averaging $441.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Atricure, Inc.$8K
- Biosense Webster, Inc.$7K
- Fidia Pharma USA Inc.$3K
- Medical Device Business Services, Inc.$1K
- Abbott$870
- Pacira Therapeutics, Inc.$591
- plus $327 from 8 others
What the payments were for
- Consulting fees$8,10037%
- Speaking & faculty fees$2,75113%
- Travel & lodging$8,81441%
- Food & beverage$1,9689%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Atricure, Inc. | 10 | $8,456 |
| Biosense Webster, Inc. | 1 | $6,750 |
| Fidia Pharma USA Inc. | 6 | $3,289 |
| Medical Device Business Services, Inc. | 2 | $1,350 |
| Abbott | 16 | $870 |
| Pacira Therapeutics, Inc. | 6 | $591 |
| Medtronic | 1 | $194 |
| Vision Quest Industries Inc. | 1 | $24 |
| Orthogenrx Inc. | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $21 |
| Amgen | 1 | $20 |
| EMD Serono, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Cardiva Medical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,632 in reported general payments places this provider in the 95th percentile of 84 nuclear medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dofetilide | 11 | $1,766 |
Paid to pharmacies, not to this prescriber.
Other nuclear medicine in New York
- Chaitanya DivgiNew York$2.2M
- Steven LarsonNew York$83K
- Ernest DepueyNew York$24K
- Chun KimNew York$22K
- Nasrin GhesaniNew York$10K
- Bilal OmeryNew York$7K
- Mikhail DoubrovinNew York$3K
- Sampanna RayamajhiNew York$2K
- Vetri Sudar JayaprakasamNew York$1K
- Heiko SchoderNew York$889
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.